Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma

References

• Shen SH, Woroniecka K, Barbour AB, Fecci PE, Sanchez-Perez L, Sampson JH. CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Expert Opin Biol Ther. 2020;20(6):579–591. doi:10.1080/14712598.2020.1727436
   PubMed Web of Science ®Google Scholar
• Le N, Do DT, Chiu FY, Yapp E, Yeh HY, Chen CY. XGBoost improves classification of MGMT promoter methylation status in IDH1 wildtype glioblastoma. J Pers Med. 2020;10(3):128.
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Kothari S, Rahman R, et al. Glioblastoma clinical trials: current landscape and opportunities for improvement. Clin Cancer Res. 2022;28(4):594–602. doi:10.1158/1078-0432.CCR-21-2750
   PubMed Web of Science ®Google Scholar
• Fisher JP, Adamson DC. Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines. 2021;9(3):324. doi:10.3390/biomedicines9030324
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–2316. doi:10.1001/jama.2017.18718
   PubMed Web of Science ®Google Scholar
• Bausart M, Préat V, Malfanti A. Immunotherapy for glioblastoma: the promise of combination strategies. J Exp Clin Cancer Res. 2022;41(1):35. doi:10.1186/s13046-022-02251-2
   PubMed Web of Science ®Google Scholar
• Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. A review of glioblastoma immunotherapy. J Neurooncol. 2021;151(1):41–53. doi:10.1007/s11060-020-03448-1
   PubMed Web of Science ®Google Scholar
• Huang B, Li X, Li Y, Zhang J, Zong Z, Zhang H. Current immunotherapies for glioblastoma multiforme. Front Immunol. 2020;11:603911. doi:10.3389/fimmu.2020.603911
   PubMed Web of Science ®Google Scholar
• Bikfalvi A, da Costa CA, Avril T, et al. Challenges in glioblastoma research: focus on the tumor microenvironment. Trends Cancer. 2023;9(1):9–27. doi:10.1016/j.trecan.2022.09.005
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang Y, Chang M, et al. Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma. Neuro Oncol. 2023;25(7):1262–1274. doi:10.1093/neuonc/noad017
   PubMed Web of Science ®Google Scholar
• Grabowski MM, Sankey EW, Ryan KJ, et al. Immune suppression in gliomas. J Neurooncol. 2021;151(1):3–12. doi:10.1007/s11060-020-03483-y
   PubMed Web of Science ®Google Scholar
• Nixon BG, Kuo F, Ji L, et al. Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer. Immunity. 2022;55(11):2044–2058.e5. doi:10.1016/j.immuni.2022.10.002
   PubMed Web of Science ®Google Scholar
• Lee E, Yong RL, Paddison P, Zhu J. Comparison of glioblastoma (GBM) molecular classification methods. Semin Cancer Biol. 2018;53:201–211. doi:10.1016/j.semcancer.2018.07.006
   PubMed Web of Science ®Google Scholar
• Ma Q, Long W, Xing C, et al. Cancer stem cells and immunosuppressive microenvironment in glioma. Front Immunol. 2018;9:2924. doi:10.3389/fimmu.2018.02924
   PubMed Web of Science ®Google Scholar
• Rodriguez S, Staicu GA, Sevastre AS, et al. Glioblastoma stem cells-useful tools in the battle against cancer. Int J Mol Sci. 2022;23(9):4602. doi:10.3390/ijms23094602
   PubMed Web of Science ®Google Scholar
• Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107–126. doi:10.1111/imr.12131
   PubMed Web of Science ®Google Scholar
• Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi:10.1038/s41408-021-00459-7
   PubMed Web of Science ®Google Scholar
• Sabbagh A, Beccaria K, Ling X, et al. Opening of the blood-brain barrier using low-intensity pulsed ultrasound enhances responses to immunotherapy in preclinical glioma models. Clin Cancer Res. 2021;27(15):4325–4337. doi:10.1158/1078-0432.CCR-20-3760
   PubMed Web of Science ®Google Scholar
• Choi BD, Yu X, Castano AP, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer. 2019;7(1):304. doi:10.1186/s40425-019-0806-7
   PubMed Web of Science ®Google Scholar
• Asmamaw Dejenie T, Tiruneh G/Medhin M, Dessie Terefe G, Tadele Admasu F, Wale Tesega W, Chekol Abebe E. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum Vaccin Immunother. 2022;18(6):2114254. doi:10.1080/21645515.2022.2114254
   PubMed Web of Science ®Google Scholar
• Chen L, Chen F, Li J, et al. CAR-T cell therapy for lung cancer: potential and perspective. Thorac Cancer. 2022;13(7):889–899. doi:10.1111/1759-7714.14375
   PubMed Web of Science ®Google Scholar
• Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM. Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro Oncol. 2020;22(10):1425–1438. doi:10.1093/neuonc/noaa154
   PubMed Web of Science ®Google Scholar
• Tudor T, Binder ZA, O’Rourke DM. CAR T Cells. Neurosurg Clin N Am. 2021;32(2):249–263. doi:10.1016/j.nec.2020.12.005
   PubMed Web of Science ®Google Scholar
• Gieryng A, Pszczolkowska D, Walentynowicz KA, Rajan WD, Kaminska B. Immune microenvironment of gliomas. Lab Invest. 2017;97(5):498–518. doi:10.1038/labinvest.2017.19
   PubMed Web of Science ®Google Scholar
• Spill F, Reynolds DS, Kamm RD, Zaman MH. Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol. 2016;40:41–48. doi:10.1016/j.copbio.2016.02.007
   PubMed Web of Science ®Google Scholar
• Woroniecka K, Chongsathidkiet P, Rhodin K, et al. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res. 2018;24(17):4175–4186. doi:10.1158/1078-0432.CCR-17-1846
   PubMed Web of Science ®Google Scholar
• Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147–167. doi:10.1038/s41571-019-0297-y
   PubMed Web of Science ®Google Scholar
• Singer LS, Feldman AZ, Buerki RA, Horbinski CM, Lukas RV, Stupp R. The impact of the molecular classification of glioblastoma on the interpretation of therapeutic clinical trial results. Chin Clin Oncol. 2021;10(4):38. doi:10.21037/cco-21-33
   PubMed Web of Science ®Google Scholar
• Śledzińska P, Bebyn M, Szczerba E, et al. Glioma 2021 WHO classification: the superiority of NGS over IHC in routine diagnostics. Mol Diagn Ther. 2022;26(6):699–713. doi:10.1007/s40291-022-00612-3
   PubMed Web of Science ®Google Scholar
• Stichel D, Ebrahimi A, Reuss D, et al. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol. 2018;136(5):793–803. doi:10.1007/s00401-018-1905-0
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110. doi:10.1016/j.ccr.2009.12.020
   PubMed Web of Science ®Google Scholar
• Wang Q, Hu B, Hu X, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017;32(1):42–56.e6. doi:10.1016/j.ccell.2017.06.003
   PubMed Web of Science ®Google Scholar
• Le N, Hung T, Do DT, Lam L, Dang LH, Huynh TT. Radiomics-based machine learning model for efficiently classifying transcriptome subtypes in glioblastoma patients from MRI. Comput Biol Med. 2021;132:104320. doi:10.1016/j.compbiomed.2021.104320
   PubMed Web of Science ®Google Scholar
• Du L, Lee JH, Jiang H, et al. β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J Exp Med. 2020;217(11):e20191115. doi:10.1084/jem.20191115
   PubMed Web of Science ®Google Scholar
• Rutledge WC, Kong J, Gao J, et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res. 2013;19(18):4951–4960. doi:10.1158/1078-0432.CCR-13-0551
   PubMed Web of Science ®Google Scholar
• Hu C, Wang K, Damon C, et al. ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma. Neuro Oncol. 2022;24(6):888–900. doi:10.1093/neuonc/noab292
   PubMed Web of Science ®Google Scholar
• Choi SI, Yin J. Prospective approaches to enhancing CAR T cell therapy for glioblastoma. Front Immunol. 2022;13:1008751. doi:10.3389/fimmu.2022.1008751
   PubMed Web of Science ®Google Scholar
• Bailey SR, Maus MV. Gene editing for immune cell therapies. Nat Biotechnol. 2019;37(12):1425–1434. doi:10.1038/s41587-019-0137-8
   PubMed Web of Science ®Google Scholar
• Chailyan A, Marcatili P, Tramontano A. The association of heavy and light chain variable domains in antibodies: implications for antigen specificity. FEBS J. 2011;278(16):2858–2866. doi:10.1111/j.1742-4658.2011.08207.x
   PubMed Web of Science ®Google Scholar
• Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561–2569. doi:10.1056/NEJMoa1610497
   PubMed Web of Science ®Google Scholar
• Lee L, Draper B, Chaplin N, et al. An April-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Blood. 2018;131(7):746–758. doi:10.1182/blood-2017-05-781351
   PubMed Web of Science ®Google Scholar
• Alabanza L, Pegues M, Geldres C, et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther. 2017;25(11):2452–2465. doi:10.1016/j.ymthe.2017.07.013
   PubMed Web of Science ®Google Scholar
• James SE, Greenberg PD, Jensen MC, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008;180(10):7028–7038. doi:10.4049/jimmunol.180.10.7028
   PubMed Web of Science ®Google Scholar
• Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol. 2010;184(12):6938–6949. doi:10.4049/jimmunol.0901766
   PubMed Web of Science ®Google Scholar
• Guedan S, Posey AD Jr, Shaw C, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight. 2018;3(1). doi:10.1172/jci.insight.96976
   Web of Science ®Google Scholar
• Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2002;20(1):70–75. doi:10.1038/nbt0102-70
   PubMed Web of Science ®Google Scholar
• O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399). doi:10.1126/scitranslmed.aaa0984
   PubMed Web of Science ®Google Scholar
• Goff SL, Morgan RA, Yang JC, et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J Immunother. 2019;42(4):126–135. doi:10.1097/CJI.0000000000000260
   PubMed Web of Science ®Google Scholar
• Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21(18):4062–4072. doi:10.1158/1078-0432.CCR-15-0428
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley V, Hegde M, et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a Phase 1 dose-escalation trial. JAMA Oncol. 2017;3(8):1094–1101. doi:10.1001/jamaoncol.2017.0184
   PubMed Web of Science ®Google Scholar
• Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934–941. doi:10.1038/s41586-022-04489-4
   PubMed Web of Science ®Google Scholar
• Lin Q, Ba T, Ho J, et al. First-in-human trial of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose. Front Oncol. 2021;11:694941. doi:10.3389/fonc.2021.694941
   PubMed Web of Science ®Google Scholar
• Jang JK, Pyo J, Suh CH, Park HS, Chae YK, Kim KW. Safety and efficacy of chimeric antigen receptor T-cell therapy for glioblastoma: a systemic review and meta-analysis. Front Oncol. 2022;12:851877. doi:10.3389/fonc.2022.851877
   PubMed Web of Science ®Google Scholar
• Feldman L, Brown C, Badie B. Chimeric Antigen Receptor (CAR) T cell therapy for glioblastoma. Neuromolecular Med. 2022;24(1):35–40. doi:10.1007/s12017-021-08689-5
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195. doi:10.1182/blood-2014-05-552729
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–851. doi:10.1038/mt.2010.24
   PubMed Web of Science ®Google Scholar
• Karschnia P, Teske N, Thon N, et al. Chimeric antigen receptor T cells for glioblastoma: current concepts, challenges, and future perspectives. Neurology. 2021;97(5):218–230. doi:10.1212/WNL.0000000000012193
   PubMed Web of Science ®Google Scholar
• Brammer JE, Braunstein Z, Katapadi A, et al. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. J Immunother Cancer. 2021;9(8):e002303. doi:10.1136/jitc-2020-002303
   PubMed Web of Science ®Google Scholar
• Rubin DB, Danish HH, Ali AB, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 2019;142(5):1334–1348. doi:10.1093/brain/awz053
   PubMed Web of Science ®Google Scholar
• Brown CE, Aguilar B, Starr R, et al. Optimization of IL13Rα2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol Ther. 2018;26(1):31–44. doi:10.1016/j.ymthe.2017.10.002
   PubMed Web of Science ®Google Scholar
• Shergalis A, Bankhead A 3rd, Luesakul U, Muangsin N, Neamati N, Barker EL. Current challenges and opportunities in treating glioblastoma. Pharmacol Rev. 2018;70(3):412–445. doi:10.1124/pr.117.014944
   PubMed Web of Science ®Google Scholar
• Lanitis E, Irving M, Coukos G. Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol. 2015;33:55–63. doi:10.1016/j.coi.2015.01.011
   PubMed Web of Science ®Google Scholar
• Palazón A, Aragonés J, Morales-Kastresana A, de Landázuri MO, Melero I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res. 2012;18(5):1207–1213. doi:10.1158/1078-0432.CCR-11-1591
   PubMed Web of Science ®Google Scholar
• Zhang D, Li AM, Hu G, et al. PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. Cell Metab. 2023;35(3):517–534.e8. doi:10.1016/j.cmet.2023.01.010
   PubMed Web of Science ®Google Scholar
• Sackstein R, Schatton T, Barthel SR. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab Invest. 2017;97(6):669–697. doi:10.1038/labinvest.2017.25
   PubMed Web of Science ®Google Scholar
• Wang G, Zhang Z, Zhong K, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther. 2023;31(1):134–153. doi:10.1016/j.ymthe.2022.08.021
   PubMed Web of Science ®Google Scholar
• Harlin H, Meng Y, Peterson AC, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009;69(7):3077–3085. doi:10.1158/0008-5472.CAN-08-2281
   PubMed Web of Science ®Google Scholar
• Andersson A, Yang SC, Huang M, et al. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol. 2009;182(11):6951–6958. doi:10.4049/jimmunol.0803340
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Charoentong P, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138(4):1429–1440. doi:10.1053/j.gastro.2009.10.057
   PubMed Web of Science ®Google Scholar
• Jin L, Tao H, Karachi A, et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019;10(1):4016. doi:10.1038/s41467-019-11869-4
   PubMed Web of Science ®Google Scholar
• Salmon H, Remark R, Gnjatic S, Merad M. Host tissue determinants of tumour immunity. Nat Rev Cancer. 2019;19(4):215–227. doi:10.1038/s41568-019-0125-9
   PubMed Web of Science ®Google Scholar
• Zhao B, Xia Y, Yang F, et al. Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor. Mol Med. 2022;28(1):34. doi:10.1186/s10020-022-00454-z
   PubMed Web of Science ®Google Scholar
• Kato D, Yaguchi T, Iwata T, et al. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):68–77. doi:10.2177/jsci.40.68
   PubMedGoogle Scholar
• Mohme M, Schliffke S, Maire CL, et al. Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes. Clin Cancer Res. 2018;24(17):4187–4200. doi:10.1158/1078-0432.CCR-17-2617
   PubMed Web of Science ®Google Scholar
• Zhu H, You Y, Shen Z, Shi L. EGFRvIII-CAR-T cells with PD-1 knockout have improved anti-glioma activity. Pathol Oncol Res. 2020;26(4):2135–2141. doi:10.1007/s12253-019-00759-1
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang Z, Zhang C, et al. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. Cancer Sci. 2018;109(9):2697–2705. doi:10.1111/cas.13744
   PubMed Web of Science ®Google Scholar
• An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37(12):1561–1575. doi:10.1038/s41388-017-0045-7
   PubMed Web of Science ®Google Scholar
• Vora P, Venugopal C, Salim SK, et al. The rational development of CD133-targeting immunotherapies for glioblastoma. Cell Stem Cell. 2020;26(6):832–844.e6. doi:10.1016/j.stem.2020.04.008
   PubMed Web of Science ®Google Scholar
• Yang YN, Zhang XH, Wang YM, Zhang X, Gu Z. miR-204 reverses temozolomide resistance and inhibits cancer initiating cells phenotypes by degrading FAP-α in glioblastoma. Oncol Lett. 2018;15(5):7563–7570. doi:10.3892/ol.2018.8301
   PubMed Web of Science ®Google Scholar
• Liu K, Jiang L, Shi Y, et al. Hypoxia-induced GLT8D1 promotes glioma stem cell maintenance by inhibiting CD133 degradation through N-linked glycosylation. Cell Death Differ. 2022;29(9):1834–1849. doi:10.1038/s41418-022-00969-2
   PubMed Web of Science ®Google Scholar
• Sangsuwannukul T, Supimon K, Sujjitjoon J, et al. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells. Int Immunopharmacol. 2020;89(Pt B):107069. doi:10.1016/j.intimp.2020.107069
   PubMed Web of Science ®Google Scholar
• Dai H, Tong C, Shi D, et al. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology. 2020;9(1):1846926. doi:10.1080/2162402X.2020.1846926
   PubMed Web of Science ®Google Scholar
• Zhu X, Prasad S, Gaedicke S, Hettich M, Firat E, Niedermann G. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget. 2015;6(1):171–184. doi:10.18632/oncotarget.2767
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang Z, Li F, et al. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma. Oncoimmunology. 2018;7(11):e1461304. doi:10.1080/2162402X.2018.1461304
   PubMed Web of Science ®Google Scholar
• Tang X, Zhao S, Zhang Y, et al. B7-H3 as a novel CAR-T therapeutic target for glioblastoma. Mol Ther Oncolytics. 2019;14:279–287. doi:10.1016/j.omto.2019.07.002
   PubMed Web of Science ®Google Scholar
• Vitanza NA, Wilson AL, Huang W, et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov. 2022;13(1):114–131.
   Web of Science ®Google Scholar
• Chaudhry K, Geiger A, Dowlati E, et al. Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β. Mol Ther Methods Clin Dev. 2022;27:415–430. doi:10.1016/j.omtm.2022.10.010
   PubMed Web of Science ®Google Scholar
• DeBin JA, Maggio JE, Strichartz GR. Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am J Physiol. 1993;264(2 Pt 1):C361–C369. doi:10.1152/ajpcell.1993.264.2.C361
   PubMedGoogle Scholar
• Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res. 1998;58(21):4871–4879.
   PubMed Web of Science ®Google Scholar
• Wang D, Starr R, Chang WC, et al. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci Transl Med. 2020;12(533). doi:10.1126/scitranslmed.aaw2672
   Web of Science ®Google Scholar
• Dardevet L, Rani D, Aziz TA, et al. Chlorotoxin: a helpful natural scorpion peptide to diagnose glioma and fight tumor invasion. Toxins. 2015;7(4):1079–1101. doi:10.3390/toxins7041079
   PubMed Web of Science ®Google Scholar
• Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene. 2008;27(45):5944–5958. doi:10.1038/onc.2008.272
   PubMed Web of Science ®Google Scholar
• Yang D, Sun B, Dai H, et al. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells. J Immunother Cancer. 2019;7(1):171. doi:10.1186/s40425-019-0642-9
   PubMedGoogle Scholar
• Zhang P, Zhang Y, Ji N. Challenges in the treatment of glioblastoma by chimeric antigen receptor T-cell immunotherapy and possible solutions. Front Immunol. 2022;13:927132. doi:10.3389/fimmu.2022.927132
   PubMed Web of Science ®Google Scholar
• Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest. 2016;126(8):3036–3052. doi:10.1172/JCI83416
   PubMed Web of Science ®Google Scholar
• Yin Y, Rodriguez JL, Li N, et al. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol Ther. 2022;30(7):2537–2553. doi:10.1016/j.ymthe.2022.05.011
   PubMed Web of Science ®Google Scholar
• Choi BD, Yu X, Castano AP, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37(9):1049–1058. doi:10.1038/s41587-019-0192-1
   PubMed Web of Science ®Google Scholar
• Bielamowicz K, Fousek K, Byrd TT, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018;20(4):506–518. doi:10.1093/neuonc/nox182
   PubMed Web of Science ®Google Scholar
• Choe JH, Watchmaker PB, Simic MS, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591). doi:10.1126/scitranslmed.abe7378
   Web of Science ®Google Scholar
• Sabahi M, Jabbari P, Alizadeh Haghighi M, et al. Proposing a tandem AND-gate CAR T cell targeting glioblastoma multiforme. Med Hypotheses. 2020;137:109559. doi:10.1016/j.mehy.2020.109559
   PubMed Web of Science ®Google Scholar
• Johnson A, Townsend M, O’Neill K. Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors. Cells. 2022;11(22):3626.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–1154. doi:10.1517/14712598.2015.1046430
   PubMed Web of Science ®Google Scholar
• Agliardi G, Liuzzi AR, Hotblack A, et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021;12(1):444. doi:10.1038/s41467-020-20599-x
   PubMed Web of Science ®Google Scholar
• Lai J, Mardiana S, House IG, et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat Immunol. 2020;21(8):914–926. doi:10.1038/s41590-020-0676-7
   PubMed Web of Science ®Google Scholar
• Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–S9. doi:10.1002/ajh.25418
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62. doi:10.1038/nrclinonc.2017.148
   PubMed Web of Science ®Google Scholar
• Singh N, Barrett DM, Grupp SA. Roadblocks to success for RNA CARs in solid tumors. Oncoimmunology. 2014;3(12):e962974. doi:10.4161/21624011.2014.962974
   PubMed Web of Science ®Google Scholar
• Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133–151. doi:10.1097/CJI.0b013e3182829903
   PubMed Web of Science ®Google Scholar
• Ong EZ, Yee JX, Ooi J, et al. Immune gene expression analysis indicates the potential of a self-amplifying Covid-19 mRNA vaccine. NPJ Vaccines. 2022;7(1):154. doi:10.1038/s41541-022-00573-y
   PubMed Web of Science ®Google Scholar
• Francis AG, Elhadd K, Camera V, et al. Acute inflammatory diseases of the central nervous system after SARS-CoV-2 vaccination. Neurol Neuroimmunol Neuroinflamm. 2023;10(1):e200063. doi:10.1212/NXI.0000000000200063
   PubMed Web of Science ®Google Scholar
• Li Y, Fang H, Zhang T, et al. Lipid-mRNA nanoparticles landscape for cancer therapy. Front Bioeng Biotechnol. 2022;10:1053197. doi:10.3389/fbioe.2022.1053197
   PubMed Web of Science ®Google Scholar
• Saha C, Bojdo J, Dunne NJ, Duary RK, Buckley N, McCarthy HO. Nucleic acid vaccination strategies for ovarian cancer. Front Bioeng Biotechnol. 2022;10:953887. doi:10.3389/fbioe.2022.953887
   PubMed Web of Science ®Google Scholar
• Rurik JG, Tombácz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91–96. doi:10.1126/science.abm0594
   PubMed Web of Science ®Google Scholar
• Gao TA, Chen YY. T cells to fix a broken heart. Science. 2022;375(6576):23–24. doi:10.1126/science.abn0851
   PubMed Web of Science ®Google Scholar
• Meister H, Look T, Roth P, et al. Multifunctional mRNA-based CAR T cells display promising antitumor activity against glioblastoma. Clin Cancer Res. 2022;28(21):4747–4756. doi:10.1158/1078-0432.CCR-21-4384
   PubMed Web of Science ®Google Scholar
• Foster JB, Griffin C, Rokita JL, et al. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors. J Immunother Cancer. 2022;10(9):e004450. doi:10.1136/jitc-2021-004450
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Hou Z, Amador-Molina A, Adusumilli PS. Regional CAR T cell therapy: an ignition key for systemic immunity in solid tumors. Cancer Cell. 2022;40(6):569–574. doi:10.1016/j.ccell.2022.04.006
   PubMed Web of Science ®Google Scholar
• Vitanza NA, Ronsley R, Choe M, et al. Locoregional CAR T cells for children with CNS tumors: clinical procedure and catheter safety. Neoplasia. 2023;36:100870. doi:10.1016/j.neo.2022.100870
   PubMed Web of Science ®Google Scholar
• Kovacs ZI, Kim S, Jikaria N, et al. Disrupting the blood-brain barrier by focused ultrasound induces sterile inflammation. Proc Natl Acad Sci U S A. 2017;114(1):E75–E84. doi:10.1073/pnas.1614777114
   PubMed Web of Science ®Google Scholar
• Touat M, Li YY, Boynton AN, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020;580(7804):517–523. doi:10.1038/s41586-020-2209-9
   PubMed Web of Science ®Google Scholar
• Sanchez-Perez LA, Choi BD, Archer GE, et al. Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One. 2013;8(3):e59082. doi:10.1371/journal.pone.0059082
   PubMed Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269–281. doi:10.1038/nri3191
   PubMed Web of Science ®Google Scholar
• Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139. doi:10.1126/scitranslmed.aac5415
   PubMed Web of Science ®Google Scholar
• Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322–3331. doi:10.1182/blood-2017-02-769208
   PubMed Web of Science ®Google Scholar
• Davies DM, Maher J. Crosstown traffic: lymphodepleting chemotherapy drives CAR T cells. Cancer Cell. 2021;39(2):138–140. doi:10.1016/j.ccell.2020.12.019
   PubMed Web of Science ®Google Scholar
• Straathof K, Flutter B, Wallace R, et al. Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. Sci Transl Med. 2020;12(571). doi:10.1126/scitranslmed.abd6169
   PubMed Web of Science ®Google Scholar
• Hong LK, Chen Y, Smith CC, et al. CD30-redirected chimeric antigen receptor T cells target CD30(+) and CD30(-) embryonal carcinoma via antigen-dependent and fas/fasl interactions. Cancer Immunol Res. 2018;6(10):1274–1287. doi:10.1158/2326-6066.CIR-18-0065
   PubMed Web of Science ®Google Scholar
• DeSelm C, Palomba ML, Yahalom J, et al. Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol Ther. 2018;26(11):2542–2552. doi:10.1016/j.ymthe.2018.09.008
   PubMed Web of Science ®Google Scholar
• Thomas P, Galopin N, Bonérandi E, Clémenceau B, Fougeray S, Birklé S. CAR T cell therapy’s potential for pediatric brain tumors. Cancers. 2021;13(21):5445. doi:10.3390/cancers13215445
   PubMed Web of Science ®Google Scholar
• Murty S, Haile ST, Beinat C, et al. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model. Oncoimmunology. 2020;9(1):1757360. doi:10.1080/2162402X.2020.1757360
   PubMed Web of Science ®Google Scholar
• Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res. 2018;78(4):1031–1043. doi:10.1158/0008-5472.CAN-17-1788
   PubMed Web of Science ®Google Scholar
• Sampson JH, Choi BD, Sanchez-Perez L, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014;20(4):972–984. doi:10.1158/1078-0432.CCR-13-0709
   PubMed Web of Science ®Google Scholar
• Huan T, Li H, Tang B. Radiotherapy plus CAR-T cell therapy to date: a note for cautions optimism. Front Immunol. 2022;13:1033512. doi:10.3389/fimmu.2022.1033512
   PubMed Web of Science ®Google Scholar
• Jarosz-Biej M, Smolarczyk R, Cichoń T, Kułach N. Tumor microenvironment as A “Game Changer” in cancer radiotherapy. Int J Mol Sci. 2019;20(13):3212. doi:10.3390/ijms20133212
   PubMed Web of Science ®Google Scholar
• Siegel R, Burock S, Wernecke KD, et al. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer. 2009;9:50. doi:10.1186/1471-2407-9-50
   PubMed Web of Science ®Google Scholar
• Lanitis E, Rota G, Kosti P, et al. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J Exp Med. 2021;218(2). doi:10.1084/jem.20192203
   PubMed Web of Science ®Google Scholar
• Al-Haideri M, Tondok SB, Safa SH, et al. CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int. 2022;22(1):365. doi:10.1186/s12935-022-02778-6
   PubMed Web of Science ®Google Scholar
• Hoyos V, Savoldo B, Quintarelli C, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010;24(6):1160–1170. doi:10.1038/leu.2010.75
   PubMed Web of Science ®Google Scholar
• Alizadeh D, Wong RA, Yang X, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res. 2019;7(5):759–772. doi:10.1158/2326-6066.CIR-18-0466
   PubMed Web of Science ®Google Scholar
• Tang L, Zheng Y, Melo MB, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018;36(8):707–716. doi:10.1038/nbt.4181
   PubMed Web of Science ®Google Scholar
• Brown CE, Rodriguez A, Palmer J, et al. Off-The-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma. Neuro Oncol. 2022;24(8):1318–1330. doi:10.1093/neuonc/noac024
   PubMed Web of Science ®Google Scholar
• Yoon DH, Osborn MJ, Tolar J, Kim CJ. Incorporation of immune checkpoint blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): combination or built-in CAR-T. Int J Mol Sci. 2018;19(2). doi:10.3390/ijms19020340
   Web of Science ®Google Scholar
• Tang OY, Tian L, Yoder T, et al. PD1 expression in EGFRvIII-directed CAR T cell infusion product for glioblastoma is associated with clinical response. Front Immunol. 2022;13:872756. doi:10.3389/fimmu.2022.872756
   PubMed Web of Science ®Google Scholar
• DiDomenico J, Lamano JB, Oyon D, et al. The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma. Oncoimmunology. 2018;7(7):e1448329. doi:10.1080/2162402X.2018.1448329
   PubMed Web of Science ®Google Scholar
• Gargett T, Yu W, Dotti G, et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther. 2016;24(6):1135–1149. doi:10.1038/mt.2016.63
   PubMed Web of Science ®Google Scholar
• Davidson TB, Lee A, Hsu M, et al. Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation. Clin Cancer Res. 2019;25(6):1913–1922. doi:10.1158/1078-0432.CCR-18-1176
   PubMed Web of Science ®Google Scholar
• Kuramitsu S, Ohno M, Ohka F, et al. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses. Cancer Gene Ther. 2015;22(10):487–495. doi:10.1038/cgt.2015.47
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhou G, Risu N, et al. Lenalidomide enhances CAR-T cell activity against solid tumor cells. Cell Transplant. 2020;29:963689720920825. doi:10.1177/0963689720920825
   PubMed Web of Science ®Google Scholar
• Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45–56. doi:10.1038/s41586-019-1593-5
   PubMed Web of Science ®Google Scholar
• Ma L, Dichwalkar T, Chang J, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365(6449):162–168. doi:10.1126/science.aav8692
   PubMed Web of Science ®Google Scholar
• Sun T, Li Y, Yang Y, Liu B, Cao Y, Yang W. Enhanced radiation-induced immunogenic cell death activates chimeric antigen receptor T cells by targeting CD39 against glioblastoma. Cell Death Dis. 2022;13(10):875. doi:10.1038/s41419-022-05319-1
   PubMed Web of Science ®Google Scholar
• Altinoz MA, Ozpinar A, Hacker E, Ozpinar A. Combining locoregional CAR-T cells, autologous + allogeneic tumor lysate vaccination and levamisole in treatment of glioblastoma. Immunopharmacol Immunotoxicol. 2022;44(6):797–808. doi:10.1080/08923973.2022.2086136
   PubMed Web of Science ®Google Scholar
• Huang M, Deng J, Gao L, Zhou J. Innovative strategies to advance CAR T cell therapy for solid tumors. Am J Cancer Res. 2020;10(7):1979–1992.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Luo Y, Da T, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 2018;3(7). doi:10.1172/jci.insight.99573
   Web of Science ®Google Scholar
• Tanoue K, Rosewell Shaw A, Watanabe N, et al. Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors. Cancer Res. 2017;77(8):2040–2051. doi:10.1158/0008-5472.CAN-16-1577
   PubMed Web of Science ®Google Scholar
• Wing A, Fajardo CA, Posey AD Jr, et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol Res. 2018;6(5):605–616. doi:10.1158/2326-6066.CIR-17-0314
   PubMed Web of Science ®Google Scholar
• Huang J, Zheng M, Zhang Z, et al. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunol Immunother. 2021;70(9):2453–2465. doi:10.1007/s00262-021-02856-0
   PubMed Web of Science ®Google Scholar
• Evgin L, Kottke T, Tonne J, et al. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med. 2022;14(640):eabn2231. doi:10.1126/scitranslmed.abn2231
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhou J, Yang X, et al. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. Mol Cancer. 2023;22(1):3. doi:10.1186/s12943-022-01711-9
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhao Y, Liu Z, et al. GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy. Transl Oncol. 2023;32:101663. doi:10.1016/j.tranon.2023.101663
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Kijima N, Hasegawa K, et al. Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for chimeric antigen receptor T cell therapy. Neurooncol Adv. 2023;5(1):vdac177. doi:10.1093/noajnl/vdac177
   PubMedGoogle Scholar